Publication | Closed Access

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Homologous Recombination DeficiencyBreast OncologyMedicineImmunologyPathologyBreast CancerCancer TreatmentCancer GeneticsOncologyNeoadjuvant Chemotherapy